Clinical Trial Detail

NCT ID NCT03962465
Title Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL (ALL 001)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Virginia
Indications

lymphoblastic lymphoma

B-cell adult acute lymphocytic leukemia

Therapies

Daunorubicin + Inotuzumab ozogamicin + Pegaspargase + Prednisone + Vincristine Sulfate

Daunorubicin + Inotuzumab ozogamicin + Prednisone + Vincristine Sulfate

Cytarabine

Methotrexate

Age Groups: adult senior

No variant requirements are available.